JP2006502167A - 全グルカン粒子および抗体を用いた癌治療 - Google Patents

全グルカン粒子および抗体を用いた癌治療 Download PDF

Info

Publication number
JP2006502167A
JP2006502167A JP2004534637A JP2004534637A JP2006502167A JP 2006502167 A JP2006502167 A JP 2006502167A JP 2004534637 A JP2004534637 A JP 2004534637A JP 2004534637 A JP2004534637 A JP 2004534637A JP 2006502167 A JP2006502167 A JP 2006502167A
Authority
JP
Japan
Prior art keywords
glucan
tumor
antibody
cells
complement
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004534637A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006502167A5 (https=
Inventor
オストロフ，ガリー，アール．
ロス，ゴードン，ディー．
Original Assignee
バイオポリマー エンジニアリング，インコーポレイテッド
ユニバーシティ オブ ルーイビル リサーチ ファウンデーション，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=31978563&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP2006502167(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by バイオポリマー エンジニアリング，インコーポレイテッド, ユニバーシティ オブ ルーイビル リサーチ ファウンデーション，インコーポレイテッド filed Critical バイオポリマー エンジニアリング，インコーポレイテッド
Publication of JP2006502167A publication Critical patent/JP2006502167A/ja
Publication of JP2006502167A5 publication Critical patent/JP2006502167A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
JP2004534637A 2002-09-04 2003-09-04 全グルカン粒子および抗体を用いた癌治療 Pending JP2006502167A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40812602P 2002-09-04 2002-09-04
PCT/US2003/027841 WO2004021994A2 (en) 2002-09-04 2003-09-04 Cancer therapy using whole glucan particles and antibodies

Publications (2)

Publication Number Publication Date
JP2006502167A true JP2006502167A (ja) 2006-01-19
JP2006502167A5 JP2006502167A5 (https=) 2006-10-19

Family

ID=31978563

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004534637A Pending JP2006502167A (ja) 2002-09-04 2003-09-04 全グルカン粒子および抗体を用いた癌治療

Country Status (9)

Country Link
US (3) US8883760B2 (https=)
EP (3) EP2181711A1 (https=)
JP (1) JP2006502167A (https=)
CN (3) CN1939335A (https=)
AT (1) ATE462437T1 (https=)
AU (2) AU2003295326A1 (https=)
CA (2) CA2496508C (https=)
DE (1) DE60331925D1 (https=)
WO (2) WO2004021994A2 (https=)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008503472A (ja) * 2004-06-16 2008-02-07 ゲーリー アール． オストロフ、 薬物送達製品および方法
WO2008023425A1 (fr) * 2006-08-24 2008-02-28 Kirin Holdings Kabushiki Kaisha Composition pour l'amélioration de l'état de la peau
US8637045B2 (en) 2004-06-16 2014-01-28 University Of Massachusetts Therapy for lysosomal enzyme deficiencies
JP2017501399A (ja) * 2013-12-05 2017-01-12 バイオセラ インコーポレイテッド β−グルカンアッセイ方法
JP2017507152A (ja) * 2014-03-05 2017-03-16 オービス ヘルス ソリューションズ エルエルシー 酵母細胞壁粒子を用いたワクチン送達系
JP2017524737A (ja) * 2014-07-10 2017-08-31 バイオセラ，インク． 腫瘍微小環境に影響する抗癌剤と組み合わせたβ−グルカン
JPWO2021049587A1 (https=) * 2019-09-11 2021-03-18
US11815435B2 (en) 2017-02-24 2023-11-14 Hibercell, Inc. Beta glucan immunopharmacodynamics

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7507724B2 (en) * 2001-01-16 2009-03-24 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US7906492B2 (en) 2001-01-16 2011-03-15 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
WO2004014320A2 (en) 2002-08-13 2004-02-19 Biopolymer Engineering, Inc. Methods of using beta glucan as a radioprotective agent
US8883760B2 (en) * 2002-09-04 2014-11-11 University Of Louisville Research Foundation, Inc. Cancer therapy using beta glucan and antibodies
US20060165700A1 (en) * 2002-09-04 2006-07-27 Ostroff Gary R Cancer therapy using whole glucan particles and antibodies
EP2070546A1 (en) 2004-04-09 2009-06-17 Takeda Pharmaceutical Company Limited Preventives/remedies for cancer
US20070059310A1 (en) * 2005-05-03 2007-03-15 Karel Steven J Therapeutic combination compositions and methods of using same
US8323644B2 (en) * 2006-01-17 2012-12-04 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US20090053221A1 (en) * 2006-01-17 2009-02-26 Cheung Nai-Kong V Immune response enhancing glucan
EP1984004A4 (en) * 2006-01-17 2010-03-03 Sloan Kettering Inst Cancer THE THERAPY REINFORCING GLUCAN
WO2007146440A2 (en) 2006-06-15 2007-12-21 Biopolymer Engineering, Inc. Dba Biothera, Inc. Glucan preparations
WO2008027580A2 (en) * 2006-09-01 2008-03-06 University Of Louisville PARTICULATE β-GLUCAN COMPOSITIONS FOR REGULATING DENDRITIC CELLS
WO2008027581A1 (en) * 2006-09-01 2008-03-06 University Of Louisville Mcrp antagonists and their uses
US9457047B2 (en) 2006-11-06 2016-10-04 Whitehead Institute Immunomodulating compositions and methods of use thereof
ES2397186T3 (es) * 2006-11-06 2013-03-05 Whitehead Institute Composiciones inmunomoduladoras y métodos para su uso
EP2222283A2 (en) 2007-10-29 2010-09-01 University of Massachusetts Yeast cell wall protein (ycwp) encapsulated multilayered nanoparticles for nucleic acid delivery (sirna)
WO2009103115A1 (en) * 2008-02-19 2009-08-27 Novogen Research Pty Ltd Evaluating the therapeutic potential of a glucan
US20110053855A1 (en) * 2008-02-19 2011-03-03 Novogen Research Pty Ltd. Ex vivo cell stimulation
WO2013040027A1 (en) * 2011-09-12 2013-03-21 Baylor Research Institute Reprogramming immune environment in breast cancer via dendritic cells
EP3363462A1 (en) 2012-04-30 2018-08-22 Biothera, Inc. Compositions and methods for beta-glucan immunotherapy
BR112014027989A2 (pt) 2012-05-07 2017-07-18 Algal Scient Corporation processo multi-etapas para produção de modulador imunológico
US9744193B2 (en) 2012-09-06 2017-08-29 Orbis Health Solutions Llc Tumor lysate loaded particles
JP6372890B2 (ja) * 2013-03-08 2018-08-15 学校法人東京理科大学 乳酸菌増殖促進剤、制御性ｔ細胞増加剤、乳酸菌増殖促進方法、制御性ｔ細胞を増加させる方法、制御性ｔ細胞増加効果の評価方法、および乳酸菌増殖促進効果の評価方法
EP2832360A1 (en) 2013-07-30 2015-02-04 Fresenius Kabi Deutschland GmbH Polysaccharide for use in preventing metastasis formation and/or relapse
LT6145B (lt) 2014-04-14 2015-04-27 Uab "Biocentras" TERAPINĖ ß-GLIUKANŲ KOMPOZICIJA, MODULIUOJANTI ŽMOGAUS IMUNINĘ SISTEMĄ IR INICIJUOJANTI VĖŽINIŲ LĄSTELIŲ ARDYMĄ
EP3215163B1 (en) 2014-11-06 2021-03-10 Biothera, Inc. Beta-glucan methods and compositions that affect the tumor microenvironment
US20180110853A1 (en) * 2016-10-21 2018-04-26 Wisconsin Alumni Research Foundation Vaccine Adjuvant
WO2018106645A1 (en) 2016-12-07 2018-06-14 Innate Biotherapeutics, Llc β-1,6-GLUCAN THERAPEUTIC ANTIBODY CONJUGATES
WO2018106644A1 (en) * 2016-12-07 2018-06-14 Innate Biotherapeutics, Llc ß-1,6-GLUCAN TRASTUZUMAB ANTIBODY CONJUGATES
CN110582209A (zh) 2017-04-10 2019-12-17 基博生物技术公司 用于消化系统健康，控制体重，增强免疫力和改善健康的多纤维益生元组合物
MX2020009510A (es) 2018-03-13 2021-08-05 Hibercell Inc Inmunoterapia combinada de beta glucano y agonista cd40.
EP3858362A1 (en) 2020-01-29 2021-08-04 Pleuran, s.r.o. Beta-glucan for use in enhancement of anti-tumor immunity in remission
EP4096685A1 (en) * 2020-01-29 2022-12-07 Pleuran, s.r.o. Beta-glucan for use in modulation of an immune response in a remission
WO2022251123A1 (en) * 2021-05-24 2022-12-01 Frank Jordan Alkaline extraction of beta glucan compounds for use in anti-viral and immune therapies
US12433915B2 (en) 2022-11-23 2025-10-07 Jjr&D, Llc Cancer cytotoxic exosome formulations and methods for use in treating cancer

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002058711A1 (en) * 2001-01-16 2002-08-01 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan

Family Cites Families (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3943247A (en) * 1972-05-22 1976-03-09 Kaken Kagaku Kabushiki Kaisha Treatment of bacterial infections with glucan compositions
US3903297A (en) 1973-11-01 1975-09-02 Upjohn Co Method of treatment and prophylaxis of gastric hypersecretion and gastric and duodenal ulcers using prostaglandin analogs
US4138479A (en) * 1975-11-07 1979-02-06 Bayer Aktiengesellschaft Process for the preparation of immunopotentiating agents from components of yeast cell wall material
JPS5461112A (en) * 1977-10-24 1979-05-17 Ono Pharmaceut Co Ltd Oncostatic polysaccharide* its preparation* and oncostatic drugs containing it as an effective component
JPS58220989A (ja) * 1982-06-14 1983-12-22 Diesel Kiki Co Ltd 可変容量式ベ−ン型圧縮機
SE456911B (sv) * 1983-12-19 1988-11-14 Olle Larm Vattenloeslig, aminerad beta-1,3-bunden d-glukan och makrofagstimulerande komposition innehaallande densamma
US4810646A (en) * 1984-11-28 1989-03-07 Massachusetts Institute Of Technology Glucan compositions and process for preparation thereof
US5250436A (en) * 1984-11-28 1993-10-05 Massachusetts Institute Of Technology Glucan compositions and process for preparation thereof
US5082936A (en) * 1984-11-28 1992-01-21 Massachusetts Institute Of Technology Glucan composition and process for preparation thereof
US5028703A (en) * 1988-03-11 1991-07-02 Massachusetts Institute Of Technology Glucan composition and process for preparation thereof
US5037972A (en) * 1984-11-28 1991-08-06 Massachusetts Institute Of Technology Glucan composition and process for preparation thereof
US4992540A (en) 1984-11-28 1991-02-12 Massachusetts Institute Of Technology Glucan composition and process for preparation thereof
CA1340080C (en) * 1985-03-11 1998-10-13 Dorothee Herlyn Human tumor therapy
US4900722A (en) * 1985-08-19 1990-02-13 Bioglucans, L.P. Methods and compositions for prophylactic and therapeutic treatment of infections
US4975421A (en) * 1985-08-19 1990-12-04 Bioglucan, Lp. Soluble phosphorylated glucan: methods and compositions for wound healing
US4739046A (en) 1985-08-19 1988-04-19 Luzio Nicholas R Di Soluble phosphorylated glucan
US5221616A (en) * 1988-07-15 1993-06-22 Quidel Corporation Prevention of spontaneous complement activation in mammalian biological fluids
KR0141685B1 (ko) * 1988-09-01 1998-07-01 야마따니 와따루 참게 아메보사이트 라이세이트 g 인자 활성화 저해제
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5057503A (en) * 1989-01-23 1991-10-15 The Brigham And Women's Hospital Derivativized polysaccharides with biologic activity, method of their isolation, and uses therefor
CA2010511A1 (en) * 1989-03-01 1990-09-01 Roberto L. Ceriani Method of enhancing cancer therapy by administration of unsaturated fatty acids
US4946450A (en) * 1989-04-18 1990-08-07 Biosource Genetics Corporation Glucan/collagen therapeutic eye shields
US5032401A (en) * 1989-06-15 1991-07-16 Alpha Beta Technology Glucan drug delivery system and adjuvant
IT1232310B (it) 1989-09-04 1992-01-28 Consiglio Nazionale Ricerche Processo per la preparazione di un prodotto contenente glucano a partire da candida albicans bmm-12
US5488040A (en) * 1989-09-08 1996-01-30 Alpha-Beta Technology, Inc. Use of neutral soluble glucan preparations to stimulate platelet production
JPH05503952A (ja) 1989-09-08 1993-06-24 アルファ　ベータ　テクノロジー，インコーポレイティッド 可溶性グルカン類の製造方法
US5811542A (en) * 1989-09-08 1998-09-22 Alpha-Beta Technology, Inc. Method for producing soluble glucans
EP0491829B1 (en) 1989-09-08 1997-06-04 Alpha Beta Technology, Inc. Composition for immune system activation
US5622939A (en) * 1992-08-21 1997-04-22 Alpha-Beta Technology, Inc. Glucan preparation
US5223491A (en) 1989-11-09 1993-06-29 Donzis Byron A Method for revitalizing skin by applying topically water insoluble glucan
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
JP2911554B2 (ja) * 1990-06-25 1999-06-23 台糖株式会社 抗ウィルス剤
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
JP3122454B2 (ja) * 1990-09-27 2001-01-09 生化学工業株式会社 カブトガニ・アメボサイト・ライセートの調製法
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
EP1820858B1 (en) 1991-03-01 2009-08-12 Dyax Corporation Chimeric protein comprising micro-protein having two or more disulfide bonds and embodiments thereof
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
IT1256035B (it) 1992-08-10 1995-11-21 Consiglio Nazionale Ricerche Glucani ad attivita' immunostimolante
US5453124A (en) * 1992-12-30 1995-09-26 Texas Instruments Incorporated Programmable multizone gas injector for single-wafer semiconductor processing equipment
US5622940A (en) * 1994-07-14 1997-04-22 Alpha-Beta Technology Inhibition of infection-stimulated oral tissue destruction by β(1,3)-glucan
GB9420645D0 (en) * 1994-10-13 1994-11-30 Dow Chemical Co Non-linear stytrenic polymer compositions and articles prepared therefrom
US5576015A (en) 1995-03-02 1996-11-19 Donzis; Byron A. Substantially purified beta (1,3) finely ground yeast cell wall glucan composition with dermatological and nutritional uses
AUPN166195A0 (en) 1995-03-13 1995-04-06 Norvet Research Pty Limited Process for glucan extraction
US6036946A (en) * 1997-12-24 2000-03-14 Shaklee Corporation Methods for protecting skin from damaging effects of ultraviolet light
ES2321892T3 (es) * 1998-09-14 2009-06-12 Nabi Biopharmaceuticals Composiciones de beta-glucanos e inmunoglobulinas especificas.
US6369216B1 (en) * 1998-09-25 2002-04-09 Biopolymer Engineering Pharmaceutical, Inc. Very high molecular weight β-glucans
US7906492B2 (en) * 2001-01-16 2011-03-15 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US7507724B2 (en) * 2001-01-16 2009-03-24 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan
US7786094B2 (en) * 2001-10-09 2010-08-31 Biopolymer Engineering, Inc. Use of beta-glucans against biological warfare weapons and pathogens including anthrax
WO2004014320A2 (en) 2002-08-13 2004-02-19 Biopolymer Engineering, Inc. Methods of using beta glucan as a radioprotective agent
US20060165700A1 (en) * 2002-09-04 2006-07-27 Ostroff Gary R Cancer therapy using whole glucan particles and antibodies
US8883760B2 (en) 2002-09-04 2014-11-11 University Of Louisville Research Foundation, Inc. Cancer therapy using beta glucan and antibodies
CN1964722A (zh) 2004-05-10 2007-05-16 生物聚合物工程有限公司 与抗生素、疫苗和病毒单克隆抗体组合的全葡聚糖颗粒

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002058711A1 (en) * 2001-01-16 2002-08-01 Sloan-Kettering Institute For Cancer Research Therapy-enhancing glucan

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JPN6010003855, ＭＩＳＡＫＩ，Ａ． ｅｔ ａｌ, "Ｓｔｒｕｃｔｕｒｅ ｏｆ ｐｅｓｔａｌｏｔａｎ， ａ ｈｉｇｈｌｙ ｂｒａｎｃｈｅｄ （１−−＞３）−ｂｅｔａ−Ｄ−ｇｌｕｃａｎ ｅｌａｂｏｒａｔｅｄ ｂｙ Ｐｅｓｔａｌｏｔｉａ ｓｐ． ８１５， ａ", Ｃａｒｂｏｈｙｄｒ Ｒｅｓ, 1984, Ｖｏｌ．１２９, ｐ．２０９−２７ *
JPN6010003857, ＣＨＥＵＮＧ，Ｎ．Ｋ． ｅｔ ａｌ, "Ｏｒａｌ （１−−＞３），（１−−＞４）−ｂｅｔａ−Ｄ−ｇｌｕｃａｎ ｓｙｎｅｒｇｉｚｅｓ ｗｉｔｈ ａｎｔｉｇａｎｇｌｉｏｓｉｄｅ ＧＤ２ ｍｏｎｏｃｌｏｎａｌ ａｎｔｉｂｏｄｙ ３Ｆ８ ｉｎ ｔｈ", Ｃｌｉｎ Ｃａｎｃｅｒ Ｒｅｓ, 200205, Ｖｏｌ．８， Ｎｏ．５, ｐ．１２１７−２３ *
JPN6010003858, ＹＡＮ，Ｊ． ｅｔ ａｌ, "Ｂｅｔａ−ｇｌｕｃａｎ， ａ "ｓｐｅｃｉｆｉｃ" ｂｉｏｌｏｇｉｃ ｒｅｓｐｏｎｓｅ ｍｏｄｉｆｉｅｒ ｔｈａｔ ｕｓｅｓ ａｎｔｉｂｏｄｉｅｓ ｔｏ ｔａｒｇｅｔ ｔｕｍｏｒｓ ｆｏｒ ｃｙｔｏｔ", Ｊ Ｉｍｍｕｎｏｌ, 1999, Ｖｏｌ．１６３， Ｎｏ．６, ｐ．３０４５−５２ *

Cited By (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9682135B2 (en) 2004-06-16 2017-06-20 University Of Massachusetts Drug delivery product and methods
US8580275B2 (en) 2004-06-16 2013-11-12 University Of Massachusetts Drug delivery product and methods
US8637045B2 (en) 2004-06-16 2014-01-28 University Of Massachusetts Therapy for lysosomal enzyme deficiencies
JP2008503472A (ja) * 2004-06-16 2008-02-07 ゲーリー アール． オストロフ、 薬物送達製品および方法
WO2008023425A1 (fr) * 2006-08-24 2008-02-28 Kirin Holdings Kabushiki Kaisha Composition pour l'amélioration de l'état de la peau
JP2017501399A (ja) * 2013-12-05 2017-01-12 バイオセラ インコーポレイテッド β−グルカンアッセイ方法
JP2019203004A (ja) * 2014-03-05 2019-11-28 オービス ヘルス ソリューションズ エルエルシー 酵母細胞壁粒子を用いたワクチン送達系
JP2017507152A (ja) * 2014-03-05 2017-03-16 オービス ヘルス ソリューションズ エルエルシー 酵母細胞壁粒子を用いたワクチン送達系
JP7311560B2 (ja) 2014-03-05 2023-07-19 オービス ヘルス ソリューションズ エルエルシー 酵母細胞壁粒子を用いたワクチン送達系
JP2021169495A (ja) * 2014-03-05 2021-10-28 オービス ヘルス ソリューションズ エルエルシー 酵母細胞壁粒子を用いたワクチン送達系
JP2017524737A (ja) * 2014-07-10 2017-08-31 バイオセラ，インク． 腫瘍微小環境に影響する抗癌剤と組み合わせたβ−グルカン
JP2021020921A (ja) * 2014-07-10 2021-02-18 バイオセラ，インク． 腫瘍微小環境に影響する抗癌剤と組み合わせたβ−グルカン
US11815435B2 (en) 2017-02-24 2023-11-14 Hibercell, Inc. Beta glucan immunopharmacodynamics
JP7088502B2 (ja) 2019-09-11 2022-06-21 株式会社アウレオ 抗体医薬の効果増強用組成物
JPWO2021049587A1 (https=) * 2019-09-11 2021-03-18

Also Published As

Publication number Publication date
WO2004030613A2 (en) 2004-04-15
US20150064199A1 (en) 2015-03-05
CN1694715B (zh) 2010-12-01
CA2496508A1 (en) 2004-04-15
WO2004030613A3 (en) 2005-01-13
EP1536820A2 (en) 2005-06-08
WO2004021994A2 (en) 2004-03-18
CA2496508C (en) 2014-04-22
AU2003295326A1 (en) 2004-04-23
CA2496596A1 (en) 2004-03-18
EP1539194A4 (en) 2007-06-13
US8883760B2 (en) 2014-11-11
AU2003268486A1 (en) 2004-03-29
CN100363054C (zh) 2008-01-23
DE60331925D1 (de) 2010-05-12
US20060009419A1 (en) 2006-01-12
CN1939335A (zh) 2007-04-04
US9522187B2 (en) 2016-12-20
EP1536820B1 (en) 2010-03-31
WO2004021994A3 (en) 2004-08-12
EP1536820A4 (en) 2007-06-20
CA2496596C (en) 2016-06-28
CN1694715A (zh) 2005-11-09
CN1697659A (zh) 2005-11-16
US20170056432A1 (en) 2017-03-02
EP1539194A2 (en) 2005-06-15
EP2181711A1 (en) 2010-05-05
EP1536820B2 (en) 2013-10-23
AU2003295326A8 (en) 2004-04-23
AU2003268486A8 (en) 2004-03-29
ATE462437T1 (de) 2010-04-15

Similar Documents

Publication Publication Date Title
CA2496596C (en) Cancer therapy using yeast insoluble .beta.-glucan particles and antibodies
US20100166751A1 (en) Cancer therapy using whole glucan particles and antibodies
US8563531B2 (en) Methods of using beta glucan as a radioprotective agent
CN1823092B (zh) 提高治疗的葡聚糖
US20080063650A1 (en) mCRP antagonists and their uses
US20090047288A1 (en) Glucan compositions and methods of enhancing CR3 dependent neutrophil-mediated cytotoxicity
EP1357919B1 (en) Therapy-enhancing glucan
US20240285700A1 (en) Combination of an oncolytic virus, an anti-pd-1 inhibitor and an activator of the innate immune system for use in the treatment of prostate cancer
EP1684777A2 (en) Effect of beta-glucan on stem cell recruitment and tissue repair
Yan β-Glucan-mediated tumor immunotherapy-mechanism of action and perspectives
MXPA06000615A (en) Therapy-enhancing glucan

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060831

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060831

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100127

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20100415

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20100422

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20101029